Sanofi and GSK take COVID-19 vaccine into Phase 3 study

By Rachel Arthur contact

- Last updated on GMT


Related tags: Sanofi, Gsk

Sanofi and GSK have started the Phase 3 study for their COVID-19 vaccine candidate: eying up potential regulatory authorization in Q4, 2021.

The study will evaluate two vaccine formulations: one against the original D.614 (Wuhan) virus and one against the B.1.351 (South Africa) variant.

The global, randomized, double-blind placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa, and Latin America.

A booster study will also complement the Phase 3 trial.

Two formulations 

The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints being the prevention of severe COVID-19 disease and prevention of asymptomatic infection.

The study will initially investigate the efficacy of a vaccine formulation targeting the original D.614 virus (Wuhan), while a second stage will evaluate a second formulation targeting the B.1.351 (South African) variant.

“Recent scientific evidence ​shows that antibodies created against the B.1.351 variant may provide broad cross-protection against other more transmissible variants,” ​note the companies, referencing a pre-print study​ published in March. “The design of the Phase 3, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants."​ 

In the coming weeks, the companies will also begin clinical studies to assess the ability of the adjuvanted recombinant-protein COVID-19 vaccine candidate to generate a strong booster response regardless of initial vaccine platform received.

Sanofi and GSK partnered up early in the pandemic to develop a adjuvanted recombinant protein-based vaccine, using Sanofi’s recombinant antigen and GSK’s pandemic adjuvant – both established platforms successful against influenza.

The project, however, suffered a setback in December when the companies announced the vaccine had shown an insufficient immune response in older people.

A refined antigen formulation entered Phase 2 trials in February.​ Interim results showed the high rates of neutralizing antibody responses in all adult age groups, with 95 to 100% seroconversion rates.

“After a single injection, high neutralizing antibody levels were also generated in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.”

The companies continue to plan for authorization in Q4, 2021: and manufacturing will begin in the coming weeks to enable rapid rollout should it be approved.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us


View more